Charcot-Marie-Tooth disease (CMT)

What changes during this transition

Charcot-Marie-Tooth disease is a family of inherited monogenic peripheral neuropathies with shared phenotype (progressive distal motor and sensory loss starting in feet and lower legs, working proximally and into hands over years to decades, with characteristic foot deformity and the 'inverted champagne bottle' lower-limb shape). It is the most common inherited neurologic disorder, with population prevalence around 1 in 2,500, and more than 100 causative genes have been identified across autosomal dominant, autosomal recessive, and X-linked inheritance patterns. The subtype taxonomy is editorially load-bearing because the genetic etiology drives prognosis, inheritance counseling, and trial enrollment eligibility. CMT1A accounts for roughly half of all CMT cases — autosomal dominant, caused by a 1.5-megabase tandem duplication on chromosome 17p11.2 that includes the PMP22 gene (peripheral myelin protein 22), producing a demyelinating neuropathy with slow nerve conduction velocities and typical childhood/adolescent onset. CMT1B is MPZ mutations. The CMT2 group comprises axonal subtypes driven by mutations in multiple different genes (MFN2, MPZ, NEFL, others), with preserved or near-normal conduction velocities but reduced amplitudes. CMT4 is the recessive demyelinating group. CMTX1 is X-linked, caused by GJB1 mutations (connexin 32), and affects males more severely than carrier females. Hereditary neuropathy with liability to pressure palsies (HNPP) is the editorially-interesting opposite of CMT1A — a PMP22 deletion (rather than duplication) producing recurrent focal pressure-palsy episodes. Genetic testing drives subtype confirmation, family counseling and reproductive decision-making, and trial-enrollment eligibility. Standard-of-care is symptomatic and supportive across the disease course because no disease-modifying therapy is currently FDA-approved for any CMT subtype. PXT3003 (Pharnext, a fixed-dose combination of low-dose baclofen, naltrexone, and sorbitol) is the most editorially current disease-modifying program — Phase 3 PREMIER trial in CMT1A produced mixed outcomes that supported an EMA marketing authorization application but did not achieve trial-design endpoints for FDA approval; the multi-jurisdictional EMA application is the load-bearing regulatory context for CMT1A patients asking about emerging therapy. AAV gene therapy programs in CMT1A (Sarepta and other sponsors) are in preclinical and early clinical development. ACE-083 (Acceleron myostatin pathway modulator) was abandoned for CMT2. NTRK signaling modulators and additional investigational programs run through the Inherited Neuropathy Consortium (INC, NIH-funded multicenter natural-history registry) and CMTA STAR + Genome to Treatments programs. The symptomatic management ladder is where the actual outcome-modifying clinical work happens: PT (gait training, balance, fall-prevention) and OT (fine-motor compensation, adaptive equipment, energy conservation) as foundation; AFO orthotics — carbon-fiber dynamic-response, posterior-leaf-spring, or solid-ankle designs depending on foot-drop severity and ankle-instability pattern — load-bearing for mobility preservation with orthotist coordination; neuropathic pain management (gabapentinoid first-line, TCA second-line, duloxetine in selected, topical lidocaine for focal pain); foot-deformity surgery (plantar fascia release, posterior tibial tendon transfer, peroneus longus-to-brevis transfer, arthrodesis) by CMT-experienced foot-and-ankle orthopedics; mobility aids progressing cane to forearm crutches to wheelchair on individual trajectory. The CMTA wallet card is the load-bearing safety document — the Charcot-Marie-Tooth Association maintains a list of medications that accelerate CMT progression. Vincristine is the most clinically load-bearing — historical pediatric ALL cases where vincristine precipitated rapid devastating CMT progression in undiagnosed CMT patients drove the recognition that this drug is absolutely contraindicated. Paclitaxel and other taxanes, cisplatin and other platinum agents, isoniazid, nitrofurantoin, amiodarone, and gold compounds also carry CMT-acceleration signals and are listed with caution. The precedent the list establishes — that a hereditary peripheral nerve disease has documented drug-class accelerators that look benign in non-CMT populations — is the editorial precedent that bears on community peptide marketing reaching this patient population. CMTA (cmtausa.org), HNF, CMT UK, Italian CMT Society, and INC anchor patient advocacy and research infrastructure. Pediatric onset typical — genetic counseling load-bearing. Pregnancy can worsen CMT symptoms in 10-20% of women. No peptide in the Juno library has a discovery-card-defensible CMT case. BPC-157's community 'nerve repair' framing reaches desperate inherited-disease patients but the pro-angiogenic VEGF-pathway mechanism is uncharacterized in inherited peripheral neuropathy and the rodent sciatic-nerve-crush corpus does not map to monogenic dysmyelination or axonopathy. NMN's NAD+-decline-in-neurodegeneration extrapolation does not engage the gene-causative mechanism in CMT. The GH-axis trio surfaces a pediatric-CMT growth-velocity question that belongs with pediatric endocrinology and the neuromuscular team, not with community GH-secretagogue prescribing; tesamorelin Rule 6 non-propagation is the sharpest of the three. Semaglutide is the obesity-coordination-of-care conversation in CMT patients with mobility limitations from progressive neuropathy. Eighty-eighth deliberate non-elevation of community peptides.